Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer

By afschroeder • October 15, 2026

Tsimberidou AM, Cabanski CR, Drakaki A, Khalil DN, Siddiqui BA, Basu S, Okrah K, Da Silva DM, Gautam S, Alayli FA, Schachter M, Fairchild J, Chin Foo W, Boffo S, Arnott J, Dugan U, Subudhi SK, Sharma P. Immune biomarkers of response and resistance to ipilimumab and nivolumab in metastatic castration-resistant prostate cancer. Sci Adv. 2026 Oct 16;12(42):eaee8730. doi: 10.1126/sciadv.aee8730. Epub 2026 Oct 14. PMID: 42873849; PMCID: PMC13666023.

Tags: Hematology/Oncology, Publications

Response to Zhang and Shi

Ji J, Cohen HJ, Sedrak MS. Response to Zhang and Shi. J Natl Cancer Inst. 2026 Oct 12:djag380. doi: 10.1093/jnci/djag380. Epub ahead of print. PMID:[...]

177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial

Kishan AU, Wilhalme H, Felix C, Enke J, Ali FZ, Nabong R, Juarez-Casillas JE, Flores K, Ma TM, Ludwig V, Nakayama M, Ells Z, Dahlbom[...]

Author Correction: PAK4 inhibition improves PD-1 blockade immunotherapy

Abril-Rodriguez G, Torrejon DY, Liu W, Zaretsky JM, Nowicki TS, Tsoi J, Puig-Saus C, Baselga-Carretero I, Medina E, Quist MJ, Garcia AJ, Senapedis W, Baloglu[...]